血管生成标志物应纳入慢性高血压并发子痫前期的诊断标准吗?
本研究回顾性分析了142例慢性高血压单胎孕妇中疑似并发子痫前期者,评估sFlt-1、PlGF及sFlt-1/PlGF比值对并发子痫前期的预测价值。结果显示sFlt-1/PlGF比值预测1周内并发子痫前期的AUC为0.91,优于PlGF的0.86(P=0.032)。将血管生成失衡加入传统ISSHP诊断标准可提高不良母儿结局的检出率,而不明显降低特异性。
要点
- 慢性高血压疑似并发子痫前期孕妇中,sFlt-1/PlGF比值预测1周内并发子痫前期优于PlGF。
- 将血管生成标志物加入传统诊断标准可提高不良母体结局检出率35.1%。
- 加入血管生成标志物可提高不良围产结局检出率20.6%,但特异性可能下降。
核心结论
- 在慢性高血压疑似并发子痫前期的孕妇中,将母血清血管生成标志物加入传统诊断标准可显著提高对母体和围产不良结局的预测敏感性,应考虑在评估中实施血管生成标志物检测。
主要发现
- 25例(17.6%)在评估后1周内发生子痫前期,52例(36.6%)在分娩前任何时间发生子痫前期,90例(63.4%)分娩时无子痫前期。
- 母血清血管生成失衡与按ISSHP标准诊断的1周内或任何时间后发生的并发子痫前期显著相关(P均<0.001)。
- sFlt-1/PlGF比值预测1周内并发子痫前期的AUC为0.91,优于PlGF的0.86(P=0.032)。
- 将血管生成失衡加入传统ISSHP诊断标准,不良母体结局综合检出率提高35.1%(95% CrI 16.6-53.6%),阳性预测值提高9.6%(95% CrI 0.0-20.6%),阴性预测值提高3.1%(95% CrI 1.3-4.9%),各预测准确性参数增加的后验概率分别>99.9%、95.6%和>99.9%,特异性无显著下降。
- 加入血管生成失衡使不良围产结局综合检出率提高20.6%(95% CrI 0.0-42.2%),后验概率96.9%,特异性下降5.7%(95% CrI -2.3%至13.6%),后验概率91.8%。
关键数值与推荐
- sFlt-1/PlGF比值预测1周内并发子痫前期的AUC为0.91,PlGF的AUC为0.86(P=0.032)。
- 加入血管生成标志物后不良母体结局检出率提高35.1%(95% CrI 16.6-53.6%)。
- 加入血管生成标志物后不良围产结局检出率提高20.6%(95% CrI 0.0-42.2%)。
临床怎么用
- 对慢性高血压疑似并发子痫前期的孕妇,可考虑检测母血清sFlt-1、PlGF及sFlt-1/PlGF比值以辅助预测并发子痫前期及不良母儿结局。
- 将血管生成标志物纳入传统诊断标准可能提高不良结局检出率,但需注意围产结局特异性可能下降。
局限性
- 本研究为单中心回顾性分析,样本量142例,结论需更大规模前瞻性研究验证。
- 原文未报告研究的具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although the most recent guidance from the International Society for the Study of Hypertension in Pregnancy (ISSHP) has highlighted the role of angiogenic marker assessment in the diagnosis of pre-eclampsia (PE) in women with chronic hypertension, the ISSHP has withheld recommending its implementation due to the limited available evidence in this group of women. Therefore, we aimed to investigate the value of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) assessment in women with chronic hypertension and suspected superimposed PE. METHODS: This was a retrospective analysis of prospectively collected data recorded in an electronic database between January 2013 and October 2019. Women with chronic hypertension and singleton pregnancy who had suspected superimposed PE were included. Superimposed PE was suspected in women presenting with worsening hypertension, epigastric pain, new-onset edema, dyspnea or neurological symptoms. The exclusion criteria were delivery within 1 week after assessment for reasons other than PE, chronic kidney disease, history of cardiac disease, fetal aneuploidy, genetic syndrome or major structural anomaly and missing pregnancy outcome. Maternal serum angiogenic markers (sFlt-1, PlGF and sFlt-1/PlGF ratio) were measured. The primary outcome was the utility of angiogenic markers in the prediction of superimposed PE. Predictive accuracy was assessed for superimposed PE diagnosed at different timepoints, including within 1 week after assessment and any time before birth. The secondary outcome was comparison of adverse maternal and perinatal outcomes between women with superimposed PE diagnosed according to the traditional ISSHP criteria and those diagnosed according to extended criteria including angiogenic markers. The predictive accuracy of each angiogenic marker was assessed using receiver-operating-characteristics-curve analysis. Area under the curve (AUC) values were compared using De Long's test. A sensitivity analysis was planned for gestational age at assessment. The association of various variables with composite adverse maternal and perinatal outcomes was assessed using binomial regression. RESULTS: The study included 142 pregnant women with chronic hypertension and suspected superimposed PE, of whom 25 (17.6%) developed PE within 1 week after assessment, 52 (36.6%) developed PE at any timepoint before birth and 90 (63.4%) delivered without PE. Maternal serum angiogenic imbalance was associated significantly with superimposed PE diagnosed according to the ISSHP criteria within 1 week or at any time after assessment (P < 0.001 for both). The predictive accuracy of maternal serum sFlt-1/PlGF ratio for superimposed PE diagnosed within 1 week after assessment was superior to that of maternal serum PlGF level (AUC, 0.91 vs 0.86; P = 0.032). The addition of angiogenic imbalance to the traditional ISSHP diagnostic criteria was associated with an increase in the detection rate (35.1% increase; 95% credible interval (CrI), 16.6-53.6%) and positive (9.6% increase; 95% CrI, 0.0-20.6%) and negative (3.1% increase; 95% CrI, 1.3-4.9%) predictive values for composite adverse maternal outcome, with high posterior probabilities of an increase in each predictive accuracy parameter (> 99.9%, 95.6% and > 99.9%, respectively), without a meaningful decrease in specificity. The addition of angiogenic imbalance improved the detection rate for composite adverse perinatal outcome (20.6% increase; 95% CrI, 0.0-42.2%), with a high posterior probability (96.9%). There was a corresponding drop in specificity (5.7% decrease; 95% CrI, -2.3% to 13.6%), with a posterior probability of 91.8%. CONCLUSIONS: In women with chronic hypertension and suspected superimposed PE, addition of maternal serum angiogenic markers to the traditional diagnostic criteria for superimposed PE improved significantly the sensitivity for the prediction of both maternal and perinatal adverse outcomes. Implementation of angiogenic marker assessment in the evaluation of pregnant women with chronic hypertension should therefore be considered. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Binder J, Kalafat E, Palmrich P, et al. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension? Ultrasound Obstet Gynecol. 2022. PMID: 34165863. doi:10.1002/uog.23711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。